To investigate the impact of the TERT mutations and MGMT methylation in IDH-wild-type GBMs, we selected IDH-wild-type GBM cases from Cohort 1 who received concurrent temozolomide and radiation therapy with a dose of 50 – 65 Gy, and whose clinical information and MGMT status were available. The gene discussed is IDH2; the disease is glioblastoma.